JP2024010053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024010053A5 JP2024010053A5 JP2023181425A JP2023181425A JP2024010053A5 JP 2024010053 A5 JP2024010053 A5 JP 2024010053A5 JP 2023181425 A JP2023181425 A JP 2023181425A JP 2023181425 A JP2023181425 A JP 2023181425A JP 2024010053 A5 JP2024010053 A5 JP 2024010053A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variant
- fragment
- lysin polypeptide
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 83
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 83
- 229920001184 polypeptide Polymers 0.000 claims description 74
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 74
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 54
- 230000002101 lytic effect Effects 0.000 claims description 42
- 241000894006 Bacteria Species 0.000 claims description 36
- 241000894007 species Species 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000588919 Citrobacter freundii Species 0.000 claims description 2
- 108010078777 Colistin Proteins 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- -1 aminoglycosides Chemical compound 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229960002100 cefepime Drugs 0.000 claims description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960000484 ceftazidime Drugs 0.000 claims description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 2
- 229950004259 ceftobiprole Drugs 0.000 claims description 2
- VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960003346 colistin Drugs 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 229960000895 doripenem Drugs 0.000 claims description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 229940118764 francisella tularensis Drugs 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 229960002182 imipenem Drugs 0.000 claims description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960002260 meropenem Drugs 0.000 claims description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 229960002292 piperacillin Drugs 0.000 claims description 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 229960001225 rifampicin Drugs 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229960004659 ticarcillin Drugs 0.000 claims description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 2
- 229960000707 tobramycin Drugs 0.000 claims description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 101710126949 Lysin Proteins 0.000 description 37
- 238000000034 method Methods 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597577P | 2017-12-12 | 2017-12-12 | |
| US62/597,577 | 2017-12-12 | ||
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US62/721,969 | 2018-08-23 | ||
| PCT/US2018/065265 WO2019118632A1 (en) | 2017-12-12 | 2018-12-12 | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| JP2020531748A JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Division JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024010053A JP2024010053A (ja) | 2024-01-23 |
| JP2024010053A5 true JP2024010053A5 (https=) | 2024-08-29 |
| JP7646237B2 JP7646237B2 (ja) | 2025-03-17 |
Family
ID=66819724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Pending JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
| JP2023181425A Active JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Pending JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12121568B2 (https=) |
| EP (1) | EP3723789A4 (https=) |
| JP (2) | JP2021506769A (https=) |
| KR (1) | KR20200098615A (https=) |
| CN (1) | CN111971058A (https=) |
| AU (1) | AU2018384790C1 (https=) |
| BR (1) | BR112020011433A2 (https=) |
| CA (1) | CA3085644A1 (https=) |
| IL (2) | IL303122A (https=) |
| MX (1) | MX2020006098A (https=) |
| WO (1) | WO2019118632A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| WO2019126670A1 (en) * | 2017-12-22 | 2019-06-27 | The Rockefeller University | Recombinant pseudomonas aeruginosa lysins |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US10988520B2 (en) | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3840771A4 (en) * | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| CN114040773A (zh) * | 2019-04-05 | 2022-02-11 | 康特拉费克特公司 | 在存在人血清的情况下对铜绿假单胞菌具有杀菌活性的溶素及其衍生物 |
| KR102225240B1 (ko) * | 2019-07-03 | 2021-03-10 | 경북대학교 산학협력단 | 다제내성 병원성 세균을 효과적으로 사멸시키는 재조합 항균 단백질 Ablysin의 용도 |
| EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corporation | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
| US20250324979A1 (en) * | 2021-09-03 | 2025-10-23 | Alexandre Ismail | LysECD7 VARIANTS AND METHODS OF USING THE SAME |
| CN114410670B (zh) * | 2022-01-29 | 2024-01-23 | 福建医科大学附属口腔医院 | 一种溶菌酶及其在口腔护理用品中的应用 |
| CN117660413B (zh) * | 2023-12-15 | 2024-06-07 | 华南理工大学 | 一种内溶素Lys009及其工程改造和应用 |
| CN120173923A (zh) * | 2025-05-08 | 2025-06-20 | 浙江大学 | 与PeiR裂解酶高维特征同源的产甲烷菌裂解酶及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| AU2010211456B2 (en) | 2009-02-06 | 2016-05-26 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
| CA2780079A1 (en) | 2009-11-18 | 2011-05-26 | Basf Plant Science Company Gmbh | Process for the production of fine chemicals |
| SG184836A1 (en) | 2010-04-27 | 2012-11-29 | Lysando Ag | Method of reducing biofilms |
| GB201018518D0 (en) | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| DK2699253T3 (en) | 2011-04-21 | 2018-07-16 | Univ Rockefeller | STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES |
| WO2015070912A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
| WO2015200783A2 (en) | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| EP4115897A1 (en) * | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| CN108103050A (zh) | 2018-02-11 | 2018-06-01 | 中国医药集团总公司四川抗菌素工业研究所 | 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用 |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3840771A4 (en) | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
-
2018
- 2018-12-12 WO PCT/US2018/065265 patent/WO2019118632A1/en not_active Ceased
- 2018-12-12 IL IL303122A patent/IL303122A/en unknown
- 2018-12-12 MX MX2020006098A patent/MX2020006098A/es unknown
- 2018-12-12 JP JP2020531748A patent/JP2021506769A/ja active Pending
- 2018-12-12 AU AU2018384790A patent/AU2018384790C1/en active Active
- 2018-12-12 IL IL275060A patent/IL275060B2/en unknown
- 2018-12-12 KR KR1020207020090A patent/KR20200098615A/ko not_active Ceased
- 2018-12-12 EP EP18889220.2A patent/EP3723789A4/en not_active Withdrawn
- 2018-12-12 CN CN201880089186.9A patent/CN111971058A/zh active Pending
- 2018-12-12 BR BR112020011433-2A patent/BR112020011433A2/pt not_active Application Discontinuation
- 2018-12-12 US US16/772,001 patent/US12121568B2/en active Active
- 2018-12-12 CA CA3085644A patent/CA3085644A1/en active Pending
-
2023
- 2023-10-20 JP JP2023181425A patent/JP7646237B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024010053A5 (https=) | ||
| JP2021519083A5 (https=) | ||
| IL277119B1 (en) | Antimicrobial lysine-peptide polypeptide templates, lysines, isolated polynucleotides encoding them and uses thereof | |
| RU2018107245A (ru) | Полипептиды лизина, активные против грамотрицательных бактерий | |
| JP2021506769A5 (https=) | ||
| JPWO2019191633A5 (https=) | ||
| JP7646237B2 (ja) | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 | |
| JPWO2020206327A5 (https=) | ||
| JPWO2020046747A5 (https=) | ||
| JP2022526978A (ja) | ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体 | |
| RU2020131450A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий | |
| JPWO2021180892A5 (https=) | ||
| JPWO2019191598A5 (https=) | ||
| JPWO2021097192A5 (https=) | ||
| RU2021137156A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных и кислотоустойчивых бактерий | |
| RU2021128336A (ru) | Лизины и их производные с бактерицидной активностью против pseudomonas aeruginosa в присутствии сыворотки крови человека | |
| HK40086790A (en) | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby | |
| RU2020129478A (ru) | Полипептидные конструкции лизин-противомикробный пептид (amp), лизины, выделенные полинуклеотиды, кодирующие их, а также варианты их применения | |
| RU2022126282A (ru) | Новый рекомбинантный лизин и его применение в лечении грамотрицательных бактериальных инфекций | |
| EP3927363A1 (en) | Recombinant antimicrobial multidomain polypeptide, methods of producing and uses thereof |